 Infusional carboplatin Phase studies infusions Twenty-two courses carboplatin Paraplatin Bristol-Meyers Evansville IN CBDCA patients advanced cancer continuous day infusion schedule days days objective trial optimal dose rate cumulative dose treatment schedule dose-limiting toxicity myelosuppression leukopenia thrombocytopenia optimal dose rate infusion total cumulative dose optimal dose rate infusion total cumulative dose times nadir levels leukocyte platelet counts days days median time recovery days days patients Grade marrow suppression pattern hematologic toxicity infusional CBDCA comparable bolus schedules clinical advantage infusional schedule CBDCA terms toxicity dose cycle dose intensity bolus schedule therapeutic advantage infusional schedule prospective comparative trial standard bolus schedule infusional schedules CBDCA delayed pattern thrombocytopenia prolonged leukopenia weeks treatment cycles